SCHEDULE: Bain Capital Life Sciences Updates Xilio Stake

Bain Capital Life Sciences entities report a 9.99% beneficial ownership stake in Xilio Therapeutics, Inc. via pre-funded warrants.

Summary

• BCLS II Equity Opportunities, LP reports beneficial ownership of 664,021 shares of Xilio Therapeutics common stock.
• The ownership stake is derived from pre-funded warrants subject to a 9.99% beneficial ownership blocker.
• The reporting entities include Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP, and BCLS II Equity Opportunities, LP.
• The calculation of the 9.99% stake is based on 5,982,839 shares of common stock outstanding as of April 28, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming existing institutional positions without signaling new strategic shifts.

Positives

• Continued institutional investment from a specialized life sciences firm.
• Clear disclosure of ownership structure and voting power arrangements.

Negatives

• The stake is limited by a 9.99% ownership blocker, preventing further immediate accumulation of voting power.

Risks

• The investment is subject to the performance and regulatory risks associated with Xilio Therapeutics' clinical pipeline.
• The 9.99% ownership blocker restricts the ability of the reporting persons to increase their influence over the issuer.

Future Outlook

The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing reflects standard institutional portfolio management within the biotechnology sector, where venture capital firms maintain significant but passive stakes in clinical-stage companies.

Comparison to Industry Standards

• The 9.99% ownership blocker is a standard provision in biotech financing to avoid triggering certain regulatory thresholds or 'change of control' provisions.
• The use of pre-funded warrants is a common mechanism in biotech capital raises to allow investors to defer share issuance until needed.

Stakeholder Impact

• Shareholders should note the continued presence of a major institutional investor, which typically provides stability to the capital structure.

Next Steps

• Continued monitoring of Xilio Therapeutics' clinical progress by the reporting persons.

Key Dates

Keywords

Xilio Therapeutics, Bain Capital Life Sciences, Schedule 13G, Beneficial Ownership, Biotech Investment, Pre-funded Warrants